• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma.

作者信息

Ruella Marco, Levine Bruce L

机构信息

1 Center for Cellular Immunotherapies, 2 Department of Pathology and Laboratory Medicine, Perelman School of Medicine, 3 Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104-5157, USA.

出版信息

Ann Transl Med. 2016 Jan;4(1):13. doi: 10.3978/j.issn.2305-5839.2015.10.11.

DOI:10.3978/j.issn.2305-5839.2015.10.11
PMID:26855949
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4716948/
Abstract
摘要

相似文献

1
Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma.智能嵌合抗原受体T细胞疗法：针对胶质母细胞瘤中靶向表皮生长因子受体变异体III（EGFRvIII）的嵌合抗原受体（CAR）T细胞的优化开发
Ann Transl Med. 2016 Jan;4(1):13. doi: 10.3978/j.issn.2305-5839.2015.10.11.
2
Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.嵌合抗原受体 T 细胞对 C57BL/6 小鼠 EGFRvIII 表达型脑胶质瘤的抗肿瘤疗效。
Biomed Pharmacother. 2019 May;113:108734. doi: 10.1016/j.biopha.2019.108734. Epub 2019 Mar 5.
3
Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.表皮生长因子受体 vIII/表皮生长因子受体双靶点嵌合抗原受体 T 细胞对胶质母细胞瘤的选择性靶向作用。
Cancer Immunol Res. 2018 Nov;6(11):1314-1326. doi: 10.1158/2326-6066.CIR-18-0044. Epub 2018 Sep 10.
4
Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.嵌合抗原受体 T 细胞靶向 EGFRvIII 治疗转移性肺癌。
Front Med. 2019 Feb;13(1):57-68. doi: 10.1007/s11684-019-0683-y. Epub 2019 Feb 5.
5
Chimeric Antigen Receptor T Cells for Glioblastoma: Current Concepts, Challenges, and Future Perspectives.用于胶质母细胞瘤的嵌合抗原受体T细胞：当前概念、挑战及未来展望
Neurology. 2021 Aug 3;97(5):218-230. doi: 10.1212/WNL.0000000000012193. Epub 2021 May 13.
6
Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma.病例报告：表皮生长因子受体III型（EGFRvIII）嵌合抗原受体（CAR）T细胞治疗复发性胶质母细胞瘤后的长期生存
Front Oncol. 2021 May 7;11:669071. doi: 10.3389/fonc.2021.669071. eCollection 2021.
7
Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma.新型高亲和力表皮生长因子受体Ⅲ型变异体（EGFRvIII）特异性嵌合抗原受体T细胞可有效清除人胶质母细胞瘤。
Clin Transl Immunology. 2021 May 9;10(5):e1283. doi: 10.1002/cti2.1283. eCollection 2021.
8
Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma.人表皮生长因子受体Ⅷ型嵌合抗原受体T细胞在原位胶质母细胞瘤中显示出良好的安全性和治疗反应。
Clin Transl Immunology. 2023 Mar 5;12(3):e1440. doi: 10.1002/cti2.1440. eCollection 2023.
9
Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma.嵌合抗原受体修饰的 T 细胞过继转移治疗胶质母细胞瘤患者中针对 EGFRvIII 的初步临床试验
J Immunother. 2019 May;42(4):126-135. doi: 10.1097/CJI.0000000000000260.
10
Novel Human NK Cell Line Carrying CAR Targeting EGFRvIII Induces Antitumor Effects in Glioblastoma Cells.携带靶向表皮生长因子受体变体Ⅲ嵌合抗原受体的新型人自然杀伤细胞系对胶质母细胞瘤细胞具有抗肿瘤作用。
Anticancer Res. 2018 Sep;38(9):5049-5056. doi: 10.21873/anticanres.12824.

引用本文的文献

1
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma.靶向表皮生长因子受体变异体Ⅲ（EGFRvIII）和白细胞介素13受体α2（IL-13Rα2）的串联嵌合抗原受体（CAR）T细胞对异质性胶质母细胞瘤有效。
Neurooncol Adv. 2022 Dec 22;5(1):vdac185. doi: 10.1093/noajnl/vdac185. eCollection 2023 Jan-Dec.
2
CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities.嵌合抗原受体 T 细胞疗法作为癌症免疫治疗的一种有前途的方法：挑战和机遇。
Cell Oncol (Dordr). 2021 Jun;44(3):495-523. doi: 10.1007/s13402-021-00593-1. Epub 2021 Mar 24.
3
Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.携带抗ERBB2嵌合抗原受体的人CD3 + T细胞在ERBB2过表达的乳腺癌细胞中表现出高效靶向性并诱导细胞凋亡。
Int J Mol Sci. 2017 Sep 8;18(9):1797. doi: 10.3390/ijms18091797.
4
EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.表皮生长因子受体作为胶质母细胞瘤治疗靶点：一个未兑现的承诺。
CNS Drugs. 2017 Sep;31(9):723-735. doi: 10.1007/s40263-017-0456-6.
5
Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.用串联双特异性抗体（TandAb）高度特异性且有效地靶向表皮生长因子受体III型变异体（EGFRvIII）阳性肿瘤
Front Oncol. 2017 May 19;7:100. doi: 10.3389/fonc.2017.00100. eCollection 2017.
6
Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.用于肿瘤免疫治疗的嵌合抗原受体T细胞疗法。
Biosci Rep. 2017 Jan 27;37(1). doi: 10.1042/BSR20160332. Print 2017 Feb 28.

本文引用的文献

1
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.嵌合抗原受体T细胞在复发难治性慢性淋巴细胞白血病中持续存在并诱导持续缓解。
Sci Transl Med. 2015 Sep 2;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.
2
Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice.亲和力优化的ErbB2或EGFR嵌合抗原受体T细胞对小鼠肿瘤的治疗指数有所提高。
Cancer Res. 2015 Sep 1;75(17):3596-607. doi: 10.1158/0008-5472.CAN-15-0159.
3
Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.调节嵌合抗原受体（CAR）对表皮生长因子受体（EGFR）密度的敏感性可在维持强大抗肿瘤活性的同时限制对正常组织的识别。
Cancer Res. 2015 Sep 1;75(17):3505-18. doi: 10.1158/0008-5472.CAN-15-0139.
4
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.人源化肿瘤特异性抗表皮生长因子受体单克隆抗体ABT-806的特性研究
Mol Cancer Ther. 2015 May;14(5):1141-51. doi: 10.1158/1535-7163.MCT-14-0820. Epub 2015 Mar 2.
5
Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.用于胶质母细胞瘤的人源化抗表皮生长因子受体变体III嵌合抗原受体T细胞的合理开发与表征
Sci Transl Med. 2015 Feb 18;7(275):275ra22. doi: 10.1126/scitranslmed.aaa4963.
6
How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia.如何训练你的T细胞：基因工程嵌合抗原受体T细胞与双特异性T细胞衔接器在B细胞急性淋巴细胞白血病中靶向CD19的比较
Expert Opin Biol Ther. 2015 Jun;15(6):761-6. doi: 10.1517/14712598.2015.1009888. Epub 2015 Feb 2.
7
Chimeric antigen receptor T cells for sustained remissions in leukemia.用于白血病持续缓解的嵌合抗原受体T细胞。
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.
8
Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.rindopepimut：一种用于治疗多形性胶质母细胞瘤的有前景的免疫疗法。
Immunotherapy. 2014;6(6):679-90. doi: 10.2217/imt.14.21.
9
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.化疗难治性弥漫性大B细胞淋巴瘤和惰性B细胞恶性肿瘤可以用表达抗CD19嵌合抗原受体的自体T细胞进行有效治疗。
J Clin Oncol. 2015 Feb 20;33(6):540-9. doi: 10.1200/JCO.2014.56.2025. Epub 2014 Aug 25.
10
T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.表达嵌合抗原受体的 T 细胞可导致人类过敏反应。
Cancer Immunol Res. 2013 Jul;1(1):26-31. doi: 10.1158/2326-6066.CIR-13-0006. Epub 2013 Apr 7.